ERBB2 and cancer: The utility of the technology was demonstrated by conjugating a Her2/ErbB2-binding Affibody with a dodecane tetraacetate chelator for use in cancer target radiolabelling and by fluorescently labelling the bacterial cell division protein FtsZ in fixed Escherichia coli cells.